These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31023480)
1. Cutaneous tumoural melanosis: a presentation of complete regression of cutaneous melanoma. Ching D; Amini E; Harvey NT; Wood BA; Mesbah Ardakani N Pathology; 2019 Jun; 51(4):399-404. PubMed ID: 31023480 [TBL] [Abstract][Full Text] [Related]
2. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules. de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207 [TBL] [Abstract][Full Text] [Related]
3. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433 [TBL] [Abstract][Full Text] [Related]
4. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma. Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
8. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967 [TBL] [Abstract][Full Text] [Related]
9. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma. García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688 [No Abstract] [Full Text] [Related]
10. Metastatic Melanoma Negative for 5 Melanocytic Markers, Complete Regressed Primary Cutaneous Melanoma, and Melanoma-Associated Leukoderma in the Same Patient. Ramos-Rodríguez C; García-Arpa M; Relea-Calatayud MF; González-López L; Romero-Aguilera G Am J Dermatopathol; 2020 Dec; 42(12):956-960. PubMed ID: 32809978 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723 [TBL] [Abstract][Full Text] [Related]
12. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil. Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328 [No Abstract] [Full Text] [Related]
13. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Yaman B; Akalin T; Kandiloğlu G Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015 [TBL] [Abstract][Full Text] [Related]
15. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783 [No Abstract] [Full Text] [Related]
16. [ Spectrum of oncogene mutations is different in melanoma subtypes]. Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785 [TBL] [Abstract][Full Text] [Related]
17. Lymph node melanosis from a primary cutaneous lesion combining a nodular (tumoral) melanosis and a congenital dermal melanocytic nevus. Rongioletti F; Pavesi A; Carli C; Parodi A; Fiocca R Am J Dermatopathol; 2012 Aug; 34(6):653-7. PubMed ID: 22456514 [TBL] [Abstract][Full Text] [Related]
18. Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. Sebaratnam DF; Martin LK; Venugopal SS; Mangos G; Freiman J; de Souza P; Farnsworth A; Cheung K; Scolyer RA; Murrell DF Int J Dermatol; 2014 Nov; 53(11):1409-11. PubMed ID: 25257244 [TBL] [Abstract][Full Text] [Related]